Rocket Pharmaceuticals (NASDAQ:RCKT) posted its earnings results on Wednesday. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04), Bloomberg Earnings reports.
Rocket Pharmaceuticals traded down $0.19, reaching $21.86, during mid-day trading on Friday, according to Marketbeat. 115,843 shares of the company’s stock traded hands, compared to its average volume of 335,833. Rocket Pharmaceuticals has a 1-year low of $3.74 and a 1-year high of $24.28. The company has a debt-to-equity ratio of 0.23, a quick ratio of 23.31 and a current ratio of 23.31.
A number of brokerages have weighed in on RCKT. William Blair began coverage on Rocket Pharmaceuticals in a research note on Wednesday. They set a “buy” rating for the company. ValuEngine upgraded Rocket Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Finally, Cowen restated a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Friday, May 11th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $27.00.
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development.
Recommended Story: NASDAQ Stock Market Explained
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.